Jefferies Healthcare Conference - 2021

Date:  2021-06-01
Author:   Dr. Sean Hall

Medlab Clinical Limited (ASX: MDC), the Australian company commercialising an enhanced drug delivery platform to maximise the efficacy of medicines has outlined its growth strategy for US and global investors at the prestigious annual Jefferies Healthcare Conference.

Medlab Clinical’s Founder, CEO and Managing Director Dr Sean Hall told the conference, “The progress of our novel synthetic cannabinoid formulation for non-opioid pain has put Medlab at the forefront of the efforts to develop clinically validated non-opioid alternatives for cancer bone pain.”

Dr Sean Hall said, “Medlab’s move to a synthetic compound for its pending Phase III trial brings greater certainty to the delivery of a pharmaceutical-grade product at industrial scale for global markets.”

Dr Sean Hall said, “Medlab was focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible.” He shared with the audience that Medlab had identified multiple revenue-generating partnering opportunities for its NanoCelle® drug delivery platform which can improve the efficacy of multiple medicines and therapeutics.

Dr Sean Hall, on behalf of Medlab, would like to thank Jefferies Financial Group Inc for the opportunity to present our vision to such an influential global audience.

Download the PowerPoint Presentation

COMMENTS 0

Tell us what you think login to share your thoughts.

ABOUT THE AUTHOR

Dr. Sean Hall, Chief Executive Officer of Medlab
Chief Executive Officer
Dr. Sean Hall

Sean founded Medlab in August 2012; he has over 20 years' experience in nutraceutical sales and development, as well as early drug discovery in Australia, Asia and the US. Sean has led and inspired his teams to author multiple patents, write peer-reviewed articles and deliver lectures at scientific conferences. His passion is leading his researchers into novel areas and strong commercialisation opportunities.

Prior Sean was a founder of FIT-BioCeuticals. Under his management and guidance, BioCeuticals became the most innovative, research-driven, practitioner brand in Australia. For his sale of FIT-BioCeuticals to Blackmores in 2012, Sean was nominated as a finalist in the inaugural Australian Exit CEO of the Year Award. Sean is a Medical Doctor with an MBA in clinical pharmaceutical management and focuses on the research to pioneer innovation and commercialisation. Sean is an active member of Medicines Australia, the European Medical Association, the American Federation for Medical Researcher, The World Medical Association, A4M and Special Operations Medical Association.